NVILE forecast ·
Moderna (MRNA) Stock Forecast: Next 30 Days
Moderna's 30-day calibrated price outlook spans an 80% range of $146.85 to $368.00 around a middle value of $232.47, against a current close of $231.01. The upcoming Q3 earnings release on 2026-11-06 is the primary catalyst: recent results days have driven a typical one-session swing of 5.5%, options markets imply a 7.2% move, and there is a 35% probability of a single-day swing exceeding 10%. Over the full 30-day window, model probabilities show a 38% chance of dropping over 10% and a 40% chance of rising over 10%.
Price now
$231.01
Nov 3, 2026
In 30 days
$232.47
NVILE forecast
Expected move
+0.6%
Range
$146.85–$368.00
What to do
- Maintain balanced position sizing and avoid unhedged directional exposure prior to the November 6 earnings release.High binary event volatility (7.2% options-implied move and 35% odds of a >10% move) makes unhedged pre-earnings bets high-risk.
- Utilize defined-risk option spreads or stop collars calibrated around the 80% distribution bounds ($146.85 and $368.00).A 30-day forecast range spanning $146.85 to $368.00 warrants structured protection against severe downside tails or post-event volatility compression.
Why
- Moderna's calibrated 30-day 80% price range is $146.85 to $368.00 under elevated volatility, reflecting essentially symmetric 10% move odds (40% up vs 38% down).
- Q3 earnings on 2026-11-06 represent the dominant near-term catalyst, with options pricing an implied move of 7.2% and a 35% chance of a single-day move over 10%.[11]
- Wall Street 12-month consensus targets average $138.37 (-40.1% vs spot), while insider Form 4 filings reveal $62.59M in open-market sales over 90 days with zero purchases.[2],[5]
- Recent momentum has been propelled by FDA acceptance and approval milestones for mRNA vaccines alongside partner progress in melanoma oncology trials.[1],[6],[10]
- Earnings revisions show short-term divergence: Zacks estimates slipped 2.6% over 30 days while 3 analysts raised current-quarter targets.[5],[7]
What could go wrong
- Consensus expects year-over-year Q3 revenue and earnings declines, creating downside risk if results miss already revised estimates.[5],[11]
- Substantial executive insider selling, including $62.6M sold across 12 transactions with zero insider purchases, signals caution at current valuation levels.[2]
- The stock's wide 80% range ($146.85 to $368.00) reflects severe potential drawdown if post-earnings implied volatility crushes premium.[1]
How it connects
- Moderna, Inc.co-developed an experimental mRNA-based cancer vaccine preventing melanoma recurrenceMerck & Co.[6]
- U.S. Food and Drug Administrationapproved mRNA flu vaccine for adults 50 and older and accepted amended BLA with August 2026 PDUFA dateModerna, Inc.[10],[1]
- Moderna, Inc.delivered first mRNA vaccines manufactured in Laval facility in partnership withGovernment of Canada[1]
- Stephane Bancelserves as CEO and sold 334,517 shares across multiple open-market filingsModerna, Inc.[2]
- Stephen Hogeserves as President and sold 77,919 shares over recent sessionsModerna, Inc.[2]
- FINRAreported daily Reg SHO short-sale volume share of 56.4%Moderna, Inc.[3]
NVILE's track record on this page
| Made | Forecast | Actual | Result |
|---|---|---|---|
| Nov 3, 2026 | $232.47 | Due Dec 3, 2026 | Pending |
Every published call is scored when it comes due. See all results →
Sources
- 1.Moderna, Inc. 10-K (2026-02-20) · sec.gov
- 2.Moderna, Inc. insider transactions (SEC Form 4) · sec.gov
- 3.MRNA daily short-sale volume (FINRA) · finra.org
- 4.Moderna, Inc. (MRNA.O) | Stock Price & Latest News | Reuters · reuters.com
- 5.MRNA Wall Street consensus: estimates, revisions, ratings, targets · finance.yahoo.com
- 6.Moderna Stock Price Doubles on Melanoma Vaccine News · wsj.com
- 7.Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know · finance.yahoo.com
- 8.MRNA stock gains over $4B in a week: Time to buy, hold or sell? · msn.com
- 9.Moderna, Inc. 10-Q (2026-07-31) · sec.gov
- 10.Moderna Stock Rises After mRNA Flu Shot Approval · wsj.com
- 11.Earnings preview: Moderna (MRNA) Q3 earnings expected to decline · msn.com
Questions
What is the Moderna forecast for the next 30 days?
NVILE's models put Moderna at about $232.47 in 30 days, +0.6% from $231.01. Moderna's 30-day calibrated price outlook spans an 80% range of $146.85 to $368.00 around a middle value of $232.47, against a current close of $231.01. The upcoming Q3 earnings release on 2026-11-06 is the primary catalyst: recent results days have driven a typical one-session swing of 5.5%, options markets imply a 7.2% move, and there is a 35% probability of a single-day swing exceeding 10%. Over the full 30-day window, model probabilities show a 38% chance of dropping over 10% and a 40% chance of rising over 10%.
What price range does NVILE expect for Moderna?
The forecast range is $146.85 to $368.00 over 30 days. Prices outside this range are possible; the range describes the model's scenarios, not a guarantee.
What could change the Moderna outlook?
Consensus expects year-over-year Q3 revenue and earnings declines, creating downside risk if results miss already revised estimates. Substantial executive insider selling, including $62.6M sold across 12 transactions with zero insider purchases, signals caution at current valuation levels. The stock's wide 80% range ($146.85 to $368.00) reflects severe potential drawdown if post-earnings implied volatility crushes premium.
What should investors watch or do about Moderna?
Maintain balanced position sizing and avoid unhedged directional exposure prior to the November 6 earnings release. Utilize defined-risk option spreads or stop collars calibrated around the 80% distribution bounds ($146.85 and $368.00).
How accurate are NVILE forecasts?
Every forecast NVILE publishes is scored against the real price when it comes due, and the results are listed on NVILE's public accuracy ledger.
This page is generated by NVILE's research models from public sources and market data. It is not financial advice, and forecasts can be wrong.